1. Generics Bulletin

Momenta plans exit of Mylan biosimilars

 
• By Dean Rudge

Momenta Pharmaceuticals has “initiated discussions” with partner Mylan to exit its participation in the development of five biosimilar programs, including the firms’ M834 biosimilar Orencia (abatacept) candidate, after completing a strategic review “aimed at reducing costs of biosimilar development” and focusing its resources on its pipeline of novel drug candidates.

Momenta Pharmaceuticals has “initiated discussions” with partner Mylan to exit its participation in the development of five biosimilar programs, including the firms’ M834 biosimilar Orencia (abatacept) candidate, after completing a strategic review “aimed at reducing costs of biosimilar development” and focusing its resources on its pipeline of novel drug candidates.

“As a result, Momenta plans to advance two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to Humira (adalimumab) and M710, its proposed biosimilar to Eylea

More from Archive

More from Generics Bulletin

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.